Sumitomo and Otsuka schizophrenia asset flunks PhIII, companies blame Covid-19 induced placebo effect
Sumitomo and Otsuka’s schizophrenia candidate ulotaront failed its Phase III test, with the companies saying that the Covid-19 pandemic pushed the placebo effect to higher-than-expected levels.
Although a placebo effect is generally anticipated to blur psychiatric trial results, preliminary data from a pair of Phase III trials, DIAMOND 1 and 2, suggested placebo may have “masked the therapeutic effect” of ulotaront, according to the companies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.